Last updated on February 2019
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Brief description of study
This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304
Clinical Study Identifier: NCT02656303
Start Over
TG Therapeutics Clinical Support Team
TG Therapeutics Investigational Trial Site Spokane, WA United States1.15miles
Connect »